CXCL10 and type 2 diabetes mellitus: Preclinical studies in patients affected by T2DM with cardiovascular complications showed an improvement in diabetic cardiomyopathy following chronic treatment with sildenafil 100 mg/d [14], as well as serum decreases of C-X-motif chemokine 10 (CXCL10) [6]—an important trigger of inflammation—and the cytokine IL-8, which is responsible for a wide range of inflammatory processes and vascular bed injury [5].